- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07613593
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease (INCLUDE-CKD)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
- Retrospective: ~450-500 existing users + matched controls(24 months data).
- Comparison with entire WKC CKD population
- Prospective: ~500-550 new users + matched controls (6 months).
- Exploratory: ~500 dialysis or pre transplant MyRenalCare users (no matched controls).
- Qualitative: 15-25 patients + 10-15 staff.
Beschreibung
Inclusion Criteria:
5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)
Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre
- Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.
- Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.
Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.
5.1.2 Inclusion criteria - matched usual care controls
Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre for chronic kidney disease.
- Not registered with or using MyRenalCare at any point during the relevant observation period.
- Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.
Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.
5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)
Patients will be eligible to take part in the qualitative interview component if they meet all of the following:
- Aged 18 years or over.
- Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.
- Able to understand spoken and written English to the extent required for participation in an interview.
- Able and willing to provide written informed consent for participation in a recorded interview.
- Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.
Clinical staff will be eligible if they meet all of the following:
- Employed by PHU or working in direct partnership with the Wessex Kidney Centre.
- Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare.
- Able and willing to provide informed consent for a recorded interview.
- Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.
Exclusion Criteria:
- Patients with acute kidney injury without established chronic kidney disease.
- Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.
- Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.
- Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).
- Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.
- Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.
- Staff members currently on extended leave or unable to participate during the data collection period.
- Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.
- Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Existing MyRenalCare users (retrospective cohort)
Adults who were already registered and actively using MyRenalCare at the start of the retrospective observation period.
Data will be collected retrospectively from their routine use of the platform.
|
Study is non-interventional.
Andere Namen:
|
|
New MyRenalCare users (prospective cohort)
Adults who are newly offered and enroll onto MyRenalCare during the defined recruitment window.
Participants will use the platform as part of routine care, and their engagement will be prospectively monitored.
|
Study is non-interventional.
Andere Namen:
|
|
Matched usual care controls
Adults with CKD receiving standard care at the Wessex Kidney Centre who are not enrolled onto MyRenalCare.
These participants receive usual clinical care without access to the MyRenalCare platform.
|
Study is non-interventional.
Andere Namen:
|
|
Patients and staff participating in qualitative interviews (qualitative cohort)
A subset of MyRenalCare users (both retrospective and prospective) and clinical staff involved in their care who are invited to take part in interviews about their experiences with MyRenalCare.
|
Study is non-interventional.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Primary
Zeitfenster: 12 months
|
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care.
Prevalence ratios will also be calculated.
|
12 months
|
|
Primary
Zeitfenster: 12-months
|
Outcome measure 2: Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation. |
12-months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
|
12-months
|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
|
12-months
|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
|
12-months
|
|
Secondary
Zeitfenster: 12-months
|
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
|
12-months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Pathologische Prozesse
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Chronische Erkrankung
- Krankheitsattribute
- Niereninsuffizienz
- Pathologische Zustände, Anzeichen und Symptome
- Niereninsuffizienz, chronisch
Andere Studien-ID-Nummern
- PHU/2024/28
- NIHR510403 (Andere Kennung: NIHR - 2025/400 i4i FAST Commissioned)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Chronisches Nierenleiden
-
Zhen LiAnmeldung auf EinladungSimultane Pankreas-Kidney-TransplantationChina
-
University Hospital, Basel, SwitzerlandNoch keine RekrutierungKardiovaskuläres kidney-metabolisches Syndrom | Cradiovaskular-Kidney-Liver-Metabolic (CKLM) -SyndromSchweiz
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanNoch keine RekrutierungAdipositas Typ 2 Diabetes Mellitus | Stoffwechselstörung-assoziierte steatotische Lebererkrankung | Kardiovaskuläres kidney-metabolisches SyndromTaiwan
-
CHU de ReimsNoch keine RekrutierungFlüssigkeitsreaktionsfähigkeit in der frühen Nach-Kidney-TransplantationsperiodeFrankreich
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterRekrutierungCytomegalovirus | Nierentransplantation; Komplikationen | Organtransplantation | Komplikationen für Lebertransplantationen | Gleichzeitige Leber-Kidney-Transplantation; KomplikationenVereinigte Staaten
-
Nanjing Medical UniversityNoch keine RekrutierungKardiovaskuläres kidney-metabolisches Syndrom
-
Hospices Civils de LyonNoch keine Rekrutierung
-
First Affiliated Hospital of Fujian Medical UniversityRekrutierungStoffwechselerkrankungen | Chronisches Nierenleiden | Herz-Kreislauf-Erkrankungen (CVD) | Kardiovaskuläres kidney-metabolisches SyndromChina
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanAbgeschlossenTyp 2 Diabetes | Nierenerkrankung | Adipositas & Übergewicht | Risikofaktor für Herz-Kreislauf-Erkrankungen | Kardiovaskuläres kidney-metabolisches Syndrom
-
University of Alabama at BirminghamOhio State University; American Heart Association; Tuskegee UniversityRekrutierungHerz-Kreislauf-Erkrankungen | Rauchen | Hypertonie | Fettleibigkeit | Diabetes | Hyperlipidämie | Nierenerkrankung | Kardiovaskuläres kidney-metabolisches SyndromVereinigte Staaten
Klinische Studien zur Non-Interventional Study
-
AstraZenecaAbgeschlossenBrustkrebs | Onkologie | EpidemiologieAlgerien
-
University of MinnesotaRekrutierungAkute PankreatitisVereinigte Staaten
-
National Taiwan University HospitalAktiv, nicht rekrutierendInfektiösen EndokarditisTaiwan
-
Northwell HealthAktiv, nicht rekrutierendHerz-Kreislauf-RisikofaktorVereinigte Staaten
-
Royal Marsden NHS Foundation TrustFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Cancer Research UK; University... und andere MitarbeiterRekrutierungSarkom | Weichgewebe-Sarkom Erwachsener | Liposarkom | Angiosarkom | Weichteilsarkom des Gliedes | Retroperitoneales Sarkom | Liposarkom, entdifferenziert | Leiomyosarkom (LMS) | Weichteilsarkom des Rumpfes und der Extremitäten | Weichteilsarkom (STS) | Sarkom, Leiomyo-, Erwachsene | Sarkom, Synovial, ErwachseneVereinigtes Königreich
-
Radicle ScienceAbgeschlossenKognitive FunktionVereinigte Staaten
-
Radicle ScienceAbgeschlossenSchmerzen | Neuropathischer Schmerz | Nozizeptiver SchmerzVereinigte Staaten
-
Apple Inc.Stanford UniversityAbgeschlossenVorhofflimmern | Arrhythmien, Herz | VorhofflatternVereinigte Staaten
-
Radicle ScienceAbgeschlossenBetonen | AngstVereinigte Staaten
-
Radicle ScienceAbgeschlossenSchlafstörung | Schlafen | SchlafstörungVereinigte Staaten